Navigation Links
Abdominal Surgery May Become Easier for Patients
Date:6/3/2009

Advanced technique is said to reduce post-op pain and scarring

WEDNESDAY, June 3 (HealthDay News) -- A scarless surgical technique shows promise in procedures such as weight-loss surgery and gallbladder and appendix removal, suggest several studies.

The technique, called Natural Orifice Translumenal Endoscopic Surgery (NOTES), causes less pain than conventional laparoscopic surgery and offers a much faster recovery time, experts say. Doctors pass an endoscope through a natural opening in the body and then through an internal incision in the stomach, vagina, bladder or colon. This eliminates external incisions and scars.

A study from the University of California, San Diego, suggests that the technique might offer a far less painful and dangerous option for weight-loss surgery. It was used to perform transvaginal sleeve gastrectomy in morbidly obese patients, creating two small incisions in the abdomen and one in the vagina to remove 70 percent of the patients' stomachs, the study reported.

The findings were to be presented this week at the Digestive Disease Week conference in Chicago.

Standard laparoscopic gastrectomy requires five to seven larger incisions in the abdomen that can cause major scarring and increase the risk for infections and hernias.

"Compared to traditional laparoscopic techniques in which patients experience a high incidence of infections and hernias, the results so far indicate this procedure accelerates weight loss while minimizing adverse events," Dr. Santiago Horgan, professor of surgery, said in a new release from a conference sponsor.

In another study, Horgan and colleagues were the first to perform transvaginal appendectomies. The procedure involved just a small incision in the abdomen and another in the vagina, fewer than the incisions needed for appendix removal with traditional laparoscopy.

"Our initial results suggest when appendectomies are pe
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. ScarArt -Creatively Camouflage Abdominal Scars
2. Action of ghrelin hormone increases appetite and favors accumulation of abdominal fat
3. Study: Vibration plate machines may aid weight loss and trim abdominal fat
4. Too Few Screened for Abdominal Aneurysm, Study Says
5. Raisin and Dried Fruit Consumption Associated With Reduced Abdominal Obesity
6. Less Invasive Interventional Treatment Can Be Recommended as First-Line Treatment for Silent Killer, Abdominal Aortic Aneurysm
7. Verathon(R) Introduces BladderScan(R) BVI 9600 Bladder Volume Instrument with AortaScan(TM) Mode to Help Physicians Identify the Presence of Abdominal Aortic Aneurysms
8. Should intra-abdominal pressure measurement be a routine for all pancreatitis patients?
9. A new screening test for chronic abdominal pain
10. 2nd Option Improves Abdominal Aorta Repair Outcomes
11. Abdominal Fat Boosts Dementia Risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Abdominal Surgery May Become Easier for Patients
Abdominal Surgery May Become Easier for Patients
Breaking Medicine Technology:Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 1Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 2Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 3Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 4Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 5Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 6Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 7Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 8Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 9Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 10Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 11ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 1ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 2ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 3Regence Wins Awards for Consumer Appeal to Transform Health Care 53156 1Regence Wins Awards for Consumer Appeal to Transform Health Care 53156 2